Professor Gary Middleton MB, BS, MD, FRCP

Professor Gary Middleton

Institute of Immunology and Immunotherapy
Professor of Medical Oncology

Contact details

Institute of Immunology and Immunotherapy
University of Birmingham
B15 2TT
Day in the life of a Professor of Medical Oncology

Gary Middleton is Professor of Medical Oncology at the University of Birmingham's Institute of Immunology and Immunotherapy and Cancer Research UK Birmingham Centre Clinical Director. He is the chief investigator on the National Lung Matrix Study and is also chief investigator of PePS2,  FOCUS4A, RUXSAC, TELOVAC, VIP and co-CI on TORCMEK.

He sits on the Lung CSG, the NCRI advanced colorectal sub-group, the NCRI pancreatic sub-group and CTAAC. His translational interests include tumour immunobiology and the tumour microenviroment with a particular focus on MDSCs and the somatic and germline drivers of an anti-cancer immune response.

Gary has worked with colleagues and oncologists treating cancer patients who test positive for COVID-19 to launch the UK Coronavirus Cancer Monitoring Project – a national project that pioneers the use of a clinician-led reporting to enable tracking of cancer patients who have tested positive for COVID-19 across the UK and analyses whether COVID-19 is affected by anti-cancer treatments. The consortium has been extremely successful with over 60 centres involved and has allowed the publication of high impact papers that document outcomes of cancer patients infected with COVID and crucially the impact of chemotherapy and immunotherapy on outcome, important in weighing up the risks and benefits for treating people with cancer.


  • MSc Clinical Oncology – Molecular Pathology of Cancer
  • MSc in Blood Sciences
  • MSc Genomic Medicine
  • BMedSc 


Emmens L, Middleton GW. The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies. Cancer Immunol Res. 2015 May;3(5):436-443.

Lal N, Beggs A, Willcox B, Middleton GW An immunogenomic stratification of colorectal cancer: implications for development of targeted immunotherapy. Oncoimmunology. 2015 Apr 2;4(3):e976052.

Beggs A, Dilworth M, Domingo E, Midgley R, Kerr D, Tomlinson IP, Middleton GW. Methylation changes in the TFAP2E promoter region are associated with BRAF mutation and poorer overall & disease free survival in colorectal cancer. Oncoscience (In Press)

Van Cutsem E, Boni C, Tabernero J, Massuti B, Middleton G, Dane F, Reichardt P, Pimentel FL, Cohn A, Follana P, Clemens M, Zaniboni A, Moiseyenko V, Harrison M, Richards DA, Prenen H, Pernot S, Ecstein-Fraisse E, Hitier S, Rougier P. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol. 2015 Jan;26(1):149-56

Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, Middleton G, de Bruin E, Le Quesne J, Shafi S, Falzon M, Horswell S, Blackhall F, Khan I, Janes S, Nicolson M, Lawrence D, Forster M, Fennell D, Lee SM, Lester J, Kerr K, Muller S, Iles N, Smith S, Murugaesu N, Mitter R, Salm M, Stuart A, Matthews N, Adams H, Ahmad T, Attanoos R, Bennett J, Birkbak NJ, Booton R, Brady G, Buchan K, Capitano A, Chetty M, Cobbold M, Crosbie P, Davies H, Denison A, Djearman M, Goldman J, Haswell T, Joseph L, Kornaszewska M, Krebs M, Langman G, MacKenzie M, Millar J, Morgan B, Naidu B, Nonaka D, Peggs K, Pritchard C, Remmen H, Rowan A, Shah R, Smith E, Summers Y, Taylor M, Veeriah S, Waller D, Wilcox B, Wilcox M, Woolhouse I, McGranahan N, Swanton C. Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. PLoS Biol. 2014 Jul 8;12(7):e1001906.

Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, Coxon F, Ross P,  Madhusudan S, Roques T, Cunningham D, Falk S, Wadd N, Harrison M, Corrie P, Iveson T, Robinson A, McAdam K, Eatock M, Evans J, Archer C, Hickish T, Garcia-Alonso A, Nicolson M, Steward W, Anthoney A, Greenhalf W, Shaw V, Costello E, Naisbitt N, Rawcliffe C, Nanson G, Neoptolemos J. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial Lancet Oncol. 2014 Jul;15(8):829-40.

Wasan H, Meade AM, Adams R, Wilson R, Pugh C, Fisher D, Sydes B, Madi A, Sizer B, Lowdell C, Middleton G, Butler R, Kaplan R, Maughan T; on behalf of the COIN-B investigators. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncol. 2014 Apr 2. pii: S1470-2045(14)70106-8.

Day AR, Middleton G, Smith RV, Jourdan IC, Rockall TA. Time to adjuvant chemotherapy following colorectal cancer resection is associated with an improved survival. Colorectal Dis. 2014 Jan 24. doi: 10.1111/codi.12570.

Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N, Blazeby JM, Dunn JA; COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014 Jan;15(1):78-86. doi: 10.1016/S1470-2045(13)70549-7

The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.  Annels NE, Shaw VE, Gabitass RF, Billingham L, Corrie P, Eatock M, Valle J, Smith D, Wadsley J, Cunningham D, Pandha H, Neoptolemos JP, Middleton G. Cancer Immunol Immunother. 2014 Feb;63(2):175-83

Ward ST, Weston CJ, Hepburn E, Damery S, Hejmadi RK, Morton DG, Middleton G, Ismail T, Adams DH. Evaluation of serum lysyl oxidase as a blood test for colorectal cancer. Eur J Surg Oncol. 2013 Nov 6. pii: S0748-7983(13)00871-8. doi: 10.1016/j.ejso.2013.10.023

Molife LR, Rudman SM, Alam S, Tan DS, Kristeleit H, Middleton G, Propper D, Bent L, Stopfer P, Uttenreuther-Fischer M, Wallenstein G, de Bono J, Spicer J. Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. Cancer Chemother Pharmacol. 2013 Dec;72(6):1213-22

Ciuleanu T, Tsai CM, Tsao CJ, Milanowski J, Amoroso D, Heo DS, Groen HJ, Szczesna A, Chung CY, Chao TY, Middleton G, Zeaiter A, Klingelschmitt G, Klughammer B, Thatcher N. phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer. 2013 Aug 13. doi:pii: S0169-5002(13)00357-7.

Middleton G, Brown S, Lowe C, Maughan T, Gwyther S, Oliver A, Richman S, Blake D, Napp V, Marshall H, Wadsley J, Maisey N, Chau I, Hill M, Gollins S, Myint S, Slater S, Wagstaff J, Bridgewater J,  Seymour M. A randomised phase III trial of the pharmacokinetic biomodulation of Irinotecan using oral ciclosporin in advanced colorectal cancer: results of the PICCOLO trial. Eur J Cancer 2013 Aug 13. doi:pii: S0959-8049(13)00492-9

Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N, Chau I, Hill M, Dawson L, Falk S, O'Callaghan A, Benstead K, Chambers P, Oliver A, Marshall H, Napp V, Quirke P. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 2013 May 28.

Waddell T, Chau I, Cunningham D, Gonzalez D, Okines ACF, Wotherspoon A, Saffrery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial Lancet Oncology 2013, April 15 April 15, 2013

Okines AF, Langley RE, Thompson LC, Stenning SP, Stevenson L, Falk S, Seymour M, Coxon F, Middleton GW, Smith D, Evans L, Slater S, Waters J, Ford D, Hall M, Iveson TJ, Petty RD, Plummer C, Allum WH, Blazeby JM, Griffin M, Cunningham D. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Ann Oncol. 2013 Mar;24(3):702-9.

Okines AF, Gonzalez de Castro D, Cunningham D, Chau I, Langley RE, Thompson LC, Stenning SP, Saffery C, Barbachano Y, Coxon F, Middleton G, Ferry D, Crosby T, Madhusudan S, Wadsley J, Waters J, Hall M, Swinson D, Robinson A, Smith D, Reis-Filho JS, Waddell TS, Puckey L, Hulkki Wilson S, Eltahir Z, Band M, Wotherspoon A. Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials. Eur J Cancer. 2013 Mar 4. doi:pii: S0959-8049(13)00115-9. 10.1016/j.ejca.2013.02.007

Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, Marshall E, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Chao D, Middleton G, Bulley S, Ngai Y, Rudd R, Hackshaw A, Boshoff C. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2012 Nov;13(11):1161-70

Gridelli C, de Marinis F, Pujol JL, Reck M, Ramlau R, Parente B, Pieters T, Middleton G, Corral J, Winfree K, Melemed S, Zimmermann A, John W, Beyrer J, Chouaki N, Visseren-Grul C, Paz-Ares LG. Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Thorac Oncol. 2012 Nov;7(11):1713-1721.

Middleton GW, Annels NE, Pandha HS. Are we ready to start studies of Th17 cell manipulation as a therapy for cancer? Cancer Immunol Immunother. 2012 Jan;61(1):1-7

Wakelee HA, Takimoto CH, Lopez-Anaya A, Chu Q, Middleton G, Dunlop D, Ramlau R, Leighl N, Rowinsky EK, Hao D, Zatloukal P, Jacobs CD, Rodon J. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2012 Feb;69(2):563-71

Wakelee HA, Middleton G, Dunlop D, Ramlau R, Leighl N, Hao D, Lopez-Anaya A, Zatloukal P, Jacobs CD. A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Cancer Chemother Pharmacol. 2011 Nov 6.

Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011 Oct;60(10):1419-30

Hirsh V, Paz-Ares L, Boyer M, Rosell R, Middleton G, Eberhardt WE, Szczesna A, Reiterer P, Saleh M, Arrieta O, Bajetta E, Webb RT, Raats J, Benner RJ, Fowst C, Meech SJ, Readett D, Schiller JH. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2011 Jul 1;29(19):2667-74.

Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O'Mahony MS, Maughan TS, Parmar M, Langley RE; FOCUS2 Investigators; National Cancer Research Institute Colorectal Cancer Clinical Studies Group. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011 May 21;377(9779):1749-59.

Gray S, Pandha HS, Michael A, Middleton G, Morgan R. HOX genes in pancreatic development and cancer. JOP. 2011 May 6;12(3):216-9

The Current Status of GV1001 and Other Telomerase Vaccination Strategies in the Treatment of Cancer VE Shaw, DJ Naisbitt, E Costello, W Greenhalf, BK Park, JP Neoptolemos and GW Middleton. Expert Rev Vaccines. 2010 Sep;9(9):1007-16. Review.

Lee SM, Woll PJ, Rudd R, O’Brien M, Ferry D, Middleton G, James L, Jitlal M, Hackshaw A. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized double-blind placebo-controlled trial. J Natl Cancer Inst. 2009 Aug 5;101(15):1049-57.

Starling N, Rao S, Cunningham D, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol. 2009 Aug 10;27(23):3786-93.

Middleton G, Ghaneh P, Costello E, Greenhalf W, Neoptolemos JP. New treatment options for advanced pancreatic cancer. Expert Rev Gastroenterol Hepatol. 2008 Oct;2(5):673-96.

Gujral DM, Bhattacharyya S, Hargreaves P, Middleton GW. Metastatic rectal adenocarcinoma within haemorrhoids: a case report. J Med Case Reports. 2008 Apr 28;2:128.

Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA 3rd. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008 May 10;26(14):2311-9. Epub 2008 Apr 7.

Gujral DM, Bhattacharyya S, Hargreaves P, Middleton GW. Periodontal disease in a patient receiving Bevacizumab: a case report. J Med Case Reports. 2008 Feb 13;2:47.

Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46.

Lordan JT, Jones RL, Karanjia ND, de Sanctis S, Woodland JG, Middleton G, Menezes N. A rare case of a retroperitoneal enterogenous cyst with in-situ adenocarcinoma. World J Surg Oncol. 2007 Oct 10;5:113.

Chau I, Cunningham D, Russell C, Norman AR, Kurzawinski T, Harper P, Harrison P, Middleton G, Daniels F, Hickish T, Prendeville J, Ross PJ, Theis B, Hull R, Walker M, Shankley N, Kalindjian B, Murray G, Gillbanks A, Black J. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer. 2006 Apr 24;94(8):1107-15.

Middleton G. Chemotherapy Trials in Colorectal Cancer.  Frontiers in Colorectal Surgery Eds Clark S and Phillips RS TFM Publishing (2005)

Chau O, Norman AR, Cunningham D, Waters JS, Topham C, Middleton G, Hill M, Ross PJ Katopodis R, Stewart G, Oates JR.  Elderly patients with Fluoropyrimidine and thymidylate synthase inhibit resistant advanced colorectal cancer derive similar benefit without excess toxicity when treated with irinotecan monotherapy.  Br. J. Cancer 2004. Oct. 18;91(8): 1453-8.

Lal R, Dickson J, Cunningham D, Chau I, Norman AR, Ross PJ, Topham C, Middleton G, Hill M, Oates J.  A randomised trial comparing defined-duration with continuous irinotecan until disease progression in Fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer.  J. Clin Oncol. 2004 Aug 1;22 (15): 3023-31.

Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, Middleton G, Sumpter K, Hill M, Oates J, Cunningham D. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin. Colorectal Cancer. 2004 Feb; 3(4)235-42.

Middleton G, The Nature of Philosophy in the Post-Genomic Era.  The Philosopher, Volume LXXXXI No. 2. 2003.

Gregory RK, Cunningham D, Fisher TA, Rhys-Evans P, Middleton GW, Bishop L, Wotherspoon A, Trott PA, Nash AG. Investigating lymphadenopathy – report on the first twelve months of the lymph node diagnostic clinic. Postgrad Med J 2000: 76:566-8.

Brown AL, Middleton G, MacVicar AD, Husband JES T1-weighted magnetic resonance imaging in breast cancer vertebral metastases: changes on treatment and correlation with response to therapy.Clin Radiol. 1998: 53(7): 493 – 501

Middleton G, Powles RL Interferon alpha and beta microglobulin in multiple myeloma. Acute Leukaemias VII. Experimental Approaches and Novel Therapies. Hiddemann et al (eds). Springer-Verlag Berlin Heidelberg 1998.

Middleton GW, Smith IE, O’Brien M, Norton A, Hickish T, Priest K, Spencer L, Ashley S. Good Symptom Relief With Palliative MVP (Mitomycin C, Vinblastine, Cisplatin) Chemotherapy in Malignant Mesothelioma. Annals of Oncology 1998; 9: 269-273.

Hickish TF, Smith IE, Nicolson MC, Ashley S, Priest K, Spencer L, Norman A, Middleton G, O’Brien MER.  A pilot study of MVP  (Mitomycin C, Vinblastine and Cisplatin) chemotherapy in small cell lung cancer. B J Cancer 1998;77:1966-1970.

Hickish TF, Smith IE, Ashley S, Middleton GW Clinical benefit from palliative chemotherapy in non-small cell lung cancer extends to the elderly and those with poor prognostic factors. B J Cancer 1998: 78(1):28-33.

Mehta J, Powles RL, Singhal S, Horton C, Middleton G, Eisen T, Meller S, Pinkerton CR, Treleaven J Early identification of patients at risk of death due to infections, haemorrhage or graft failure after allogeneic bone marrow transplantation on the basis of the leucocyte count. Bone Marrow Transplantation 1997: 19: 349-355.

Raje N, Powles R, Milan S, Middleton G, Singhal S, Mehta J, Millar B D, Viner C, Raymond J, Treleaven J, Cunningham D, Gore M. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. B J Haematol 1997;97; 155-160.

Raje N, Powles RL, Horton C, Millar B, Shepherd V, Middleton G, Kulkharni S, Eisen T, Singhal S, Treleaven J.  Comparison of marrow vs. blood-derived stem-cells for autografting in previously untreated multiple myeloma. British Journal of Cancer 1997: 75: 1684-1689.

Mehta J, Powles R L, Treleaven J, Horton C, Shepherd V, Meller S, Pinkerton CR, Middleton G W, Eisen T, Singhal S.  Long-term follow up of patients undergoing allogeneic bone marrow transplanattion for acute myeloid leukaemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. Bone Marrow Transplantation 1996: 18: 741-746

Mehta J, Powles R, Singhal S, Matthey F, Hamblin M, Middleton G, Prendiville J, Glynne P, Zomas A, Treleaven J, Catovsky D. T cell-depleted allogeneic bone marrow transplantation from a partially HLA-mismatched unrelated donor for progressive chronic lymphocytic leukemia and fludarabine-induced bone marrow failure. Bone Marrow Transplant. 1996 May;17(5):881-3.

Millar B C, Bell J B G, Raje N, Milan S, Mehta J, Singhal S, Middleton G W, Shepherd V, Catovsky D, Powles R L.  The role of CD34+ cells in engraftment after high dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue. Bone Marrow Transplantation 1996: 18: 871-878

Middleton G W, Cunningham D.  In: “Cancer: How worthwhile is non-curative treatment?”  “Chemotherapy for Cancer of the Colon.”  Ed: Slevin M, Tate T.  Pub: Springer Cancer Series, Springer Verlag London Ltd 

Bamias A, Hill M, Cunningham D, Norman A, Ahmed F, Webb A, Middleton G W, Watson M, Hill A, Nicolson M, O’Brien M E R, Evans C, Nicolson V.  ECF (Epirubicin, Cisplatin and Protracted Venous Infusion 5-FU) for Oesophagogastric Carcinoma: Response, Toxicity, Quality of Life and Survival. Cancer 1996: 77: 1978-1985

Hill M, Normal A, Cunningham D, Findlay M, Watson M, Nicolson V, Webb A, Middleton G W, Ahmed F, Hickish T F, Nicolson M, O’Brien M, Iveson T, Iveson A, Evans C.  Impact of protracted venous infusion 5FU with or without Interferon Alfa 2B on tumour response, survival and quality of life in advanced colorectal cancer.  Journal of Clinical Oncology 1995; 13: No 9, 2317 - 2323

Hickish T F, Smith I E, Middleton G W, Nicolson M. Patient preference for extended palliative chemotherapy for non-small cell lung cancer.  Lancet 1995; 345: 857 - 858

Hickish T F, Smith I E, Ashley S, Middleton G W.  Chemotherapy for elderly patients with lung cancer.  Lancet 1995; 346: 580

Anderson J R, Armitage J O, Vose J M, Bierman P, Weisenburger D, Cunningham D, O’Brien M E R, Middleton G W, Webb A, Mead G M, Whitehouse J M, Proctor S J.  ChlVPP therapy for Hodgkin’s Disease: experience of 960 patients.  Annals of Oncology 1995;  6: 167 - 172

Middleton G W, Cunningham D.  Current options in the management of gastrointestinal cancer.  Annals of Oncology 1995; 6: (S1) S17 -S26

Crawford D H, Middleton G W, Thomas J A et al: Pathology associated with Epstein-Barr virus (EBV) and acquired immunodeficiency syndrome (AIDS).  The Epstein-Barr Virus and Associated Diseases.  1993; 225: 631 - 635

Sheldon CD, Middleton GW, Hughes DT, Forster GE.  Rapid pulmonary cavitation due to Mycobacterium Tuberculosis and infection with human immunodeficiency virus (HIV 1). Postgrad Med J 1992: 68:302-303

Middleton G W, Lau R K W.  Aids Lymphomas [Editorial]. Int J STD and AIDS 1992; 3: 173 – 181

View all publications in research portal